Who are Antiarrhythmic drug (AAD)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Corvert (Ibutilide), Amiodarone i.v., iv Procainamide, iv Amiodarone, Propafenone i.v., Intravenous amiodarone(2).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/antiarrhythmic-drug-aad.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Antiarrhythmic drug (AAD) — Competitive Intelligence Brief

Antiarrhythmic drug (AAD) (Antiarrhythmic drug (AAD)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiarrhythmic agent. Area: Cardiovascular.

marketed Antiarrhythmic agent Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Antiarrhythmic drug (AAD) (Antiarrhythmic drug (AAD)) — Kyoto University, Graduate School of Medicine. Antiarrhythmic drugs work by modulating cardiac electrical activity to restore normal heart rhythm.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Antiarrhythmic drug (AAD) TARGET	Antiarrhythmic drug (AAD)	Kyoto University, Graduate School of Medicine	marketed	Antiarrhythmic agent
Corvert (Ibutilide)	Corvert (Ibutilide)	Medical University of Vienna	marketed	Class III antiarrhythmic agent	Delayed rectifier potassium channels (hERG); sodium channels
Amiodarone i.v.	Amiodarone i.v.	Charles University, Czech Republic	marketed	Class III antiarrhythmic agent	Potassium channels (hERG); also sodium channels, beta-adrenergic receptors, and calcium channels
iv Procainamide	iv Procainamide	Hospital General Universitario Gregorio Marañon	marketed	Class IA antiarrhythmic agent	Cardiac voltage-gated sodium channel
iv Amiodarone	iv Amiodarone	Hospital General Universitario Gregorio Marañon	marketed	Class III antiarrhythmic agent	Potassium channels (hERG), sodium channels, calcium channels, beta-adrenergic receptors
Propafenone i.v.	Propafenone i.v.	Charles University, Czech Republic	marketed	Class IC antiarrhythmic agent	Cardiac sodium channel (Nav1.5)
Intravenous amiodarone(2)	Intravenous amiodarone(2)	Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud	marketed	Class III antiarrhythmic agent	Potassium channels (hERG), sodium channels, beta-adrenergic receptors, calcium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiarrhythmic agent class)

Hospital San Carlos, Madrid · 1 drug in this class
Kyoto University, Graduate School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Antiarrhythmic drug (AAD) — Competitive Intelligence Brief. https://druglandscape.com/ci/antiarrhythmic-drug-aad. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab